The role of RRM2 in the proliferation and drug sensitivity of gastric cancer cells was determined by knocking down (KD) or overexpressing (OE) RRM2 before treatment with 5-FU, HZ-A-018 or the combination (Figure 6A). The gene discussed is RRM2; the disease is gastric cancer.